EBITDA for AbbVie (ABBV)
According to AbbVie's latest reported financial statements, the company's current EBITDA (TTM) is $17.63B USD. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
ABBV
Currently viewingEBITDASwitch metric
TTM (last 4 quarters)
$17.63B
YoY change
+18.2%
5Y CAGR
+7.4%
Peak year (2022)
$24.17B
Cumulative EBITDA
$193.23B
EBITDA history chart for AbbVie (ABBV) from 2009 to 2025
EBITDA history table for AbbVie (ABBV) from 2009 to 2025
| Fiscal year | Period ended | Reported | EBITDA | YoY |
|---|---|---|---|---|
| 2025 | $17.63B | +18.2% | ||
| 2024 | $14.91B | -13.2% | ||
| 2023 | $17.17B | -29.0% | ||
| 2022 | $24.17B | +1.0% | ||
| 2021 | $23.93B | +94.2% | ||
| 2020 | $12.32B | +0.8% | ||
| 2019 | $12.23B | +47.1% | ||
| 2018 | $8.31B | -19.9% | ||
| 2017 | $10.38B | +2.5% | ||
| 2016 | $10.12B | +23.4% | ||
| 2015 | $8.20B | +128.8% | ||
| 2014 | $3.58B | -45.1% | ||
| 2013 | $6.53B | -6.5% | ||
| 2012 | $6.98B | +41.3% | ||
| 2011 | $4.94B | -17.9% | ||
| 2010 | $6.02B | +3.8% | ||
| 2009 | $5.80B | — |
EBITDA values are taken from AbbVie's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
AbbVie (ABBV) most recent annual EBITDA stands at $17.63B (2025) – grew 18.2% year-over-year.
Over 2020–2025 (5 years), AbbVie EBITDA expanded at a +7.4% compound annual rate, with the latest reading among the more recent periods of the dataset.
AbbVie EBITDA declined from $24.17B in 2022 to $17.63B in 2025, a 27.1% drawdown.
$24.17B stands as the all-time-high annual EBITDA, posted in 2022, against a low of $3.58B during 2014.
Among 8 Healthcare peers, AbbVie (ABBV) ranks 7th; the peer median for EBITDA is $24.21B.
AbbVie EBITDA by Year
AbbVie EBITDA 2025: $17.63B
AbbVie EBITDA in 2025 was $17.63B, grew 18.2% from 2024.
AbbVie EBITDA 2024: $14.91B
AbbVie EBITDA in 2024 was $14.91B, declined 13.2% below 2023.
AbbVie EBITDA 2023: $17.17B
AbbVie EBITDA in 2023 was $17.17B, declined 29.0% below 2022.
AbbVie EBITDA 2022: $24.17B
AbbVie EBITDA in 2022 was $24.17B, edged up 1.0% from 2021. This figure represents the highest annual value in the available history.
AbbVie EBITDA 2021: $23.93B
AbbVie EBITDA in 2021 was $23.93B.
See more financial history for AbbVie (ABBV).
Sector peers — EBITDA
Companies in the same sector as AbbVie, ranked by their latest EBITDA.
| Company | EBITDA | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $156.73B | Healthcare |
| Johnson & Johnson (JNJ) | $41.05B | Healthcare |
| Eli Lilly and Company (LLY) | $27.94B | Healthcare |
| Merck & Co., Inc. (MRK) | $25.36B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $23.06B | Healthcare |
| AstraZeneca PLC (AZN) | $19.83B | Healthcare |
| Amgen Inc. (AMGN) | $15.84B | Healthcare |
| Thermo Fisher Scientific Inc. (TMO) | $11.47B | Healthcare |
Frequently asked questions
What is AbbVie's EBITDA?
- Latest reported EBITDA for AbbVie (ABBV) is $17.63B (period ending December 31, 2025).
How has AbbVie EBITDA changed year-over-year?
- AbbVie (ABBV) EBITDA changed +18.2% year-over-year on the latest annual filing.
What is the long-term growth rate of AbbVie EBITDA?
- AbbVie (ABBV) EBITDA compound annual growth rate is +7.4% over the most recent 5 years available.
When did AbbVie EBITDA hit its highest annual value?
- AbbVie EBITDA reached its highest annual value of $24.17B in 2022.
What was AbbVie EBITDA in 2024?
- AbbVie (ABBV) EBITDA in 2024 was $14.91B.
What was AbbVie EBITDA in 2025?
- AbbVie (ABBV) EBITDA in 2025 was $17.63B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
ABBV Overview
Company profile, financial tools, and key metrics
ABBV Revenue Counter
Earns $1,939 every second. See per minute, hour, and day.
ABBV Earnings Counter
Earns $134.01 per second net profit. See per minute, hour, and day.
ABBV Economic Scale
Exceeds Bolivia's GDP. Compare with world economies.
ABBV What If Invested
What if you had invested $1,000? See historical returns from any date.
ABBV How It Makes Money
Discover visual breakdown of $61.16B in revenue — where it comes from and where it goes.
ABBV Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
ABBV Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
ABBV Daily Price Character
Steady · 53.5% historical win rate (green days). Streaks & record days.
ABBV Buybacks
0.24% TTM buyback yield. Shareholder yield & SBC comparison.
ABBV Dividend Profile
Yield: 3.31%. Safety: 6/8. See full history.
ABBV Dividend Calculator
How much dividend income would $1,000 have earned? Calculate from any date.
ABBV Dividend Forecast
Project future income with DRIP, growth assumptions, and optional monthly contributions.